Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14342MR)

This product GTTS-WQ14342MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ANGPT2&VEGFA gene. The antibody can be applied in Diabetic macular edema, Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens; Humanized
RefSeq NM_001118887.2; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285; 7422
UniProt ID O15123; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14342MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7036MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Fab C225
GTTS-WQ1392MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABT-981
GTTS-WQ6363MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ15555MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ86MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 1121B
GTTS-WQ10412MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY2439821
GTTS-WQ2439MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 157
GTTS-WQ15862MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA XmAb5871
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW